Dr. Marasco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Jfb 824
Boston, MA 02115Phone+1 617-632-2153
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1988 - 1990
- University of MichiganResidency, Internal Medicine, 1986 - 1988
- University of Michigan Medical SchoolClass of 1986
Certifications & Licensure
- MA State Medical License 1988 - 2025
- MI State Medical License 1987 - 1991
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- 52 citationsA Novel Framework for Characterizing Genomic Haplotype Diversity in the Human Immunoglobulin Heavy Chain Locus.Oscar L. Rodriguez, William S. Gibson, Tom Parks, Matthew Emery, James C. Powell
Frontiers in Immunology. 2020-09-23 - 192 citationsIdentification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolutionXianchun Tang, Sudhakar Agnihothram, Yongjun Jiao, Jeremy Stanhope, Rachel L. Graham
Proceedings of the National Academy of Sciences of the United States of America. 2014-05-13 - 77 citationsThe Individual and Population Genetics of Antibody Immunity.Corey T. Watson, Jacob Glanville, Wayne A. Marasco
Trends in Immunology. 2017-07-01
Journal Articles
- Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance Against a Broadly Neutralizing Hemagglutinin Stem AntibodyRobert W Finberg, Wayne A Marasco, Jennifer P Wang, mBio
Press Mentions
- FDA Advisers Vote to Include an Omicron-Specific Component for a Coronavirus Booster in the USJune 28th, 2022
- Pfizer, Moderna, Novavax: FDA Experts Vote 19-2 to Include Omicron Shot in Covid BoostersJune 28th, 2022
- 13 Notable Pioneers in the Field of MedicineJanuary 2nd, 2021
- Join now to see all
Grant Support
- Study Of Broadly Neutralizing Antibody Generation To HIV Gp140 In Humanized MiceNational Institute Of Allergy And Infectious Diseases2010–2011
- Broad Spectrum Neutralizing Human Abs To SARS And Related CoronavirusesNational Institute Of Allergy And Infectious Diseases2010–2011
- Spore Core 1: Administrative, Evaluation And PlanningNational Cancer Institute2009–2011
- Human MAB Cocktails To Prevent &Treat H5N1 Avian InfluenzaNational Institute Of Allergy And Infectious Diseases2007–2011
- Anti-Hiv-1 TAT Human SFV Intrabody Gene Therapy Against SHIV In Rhesus MacaquesNational Center For Research Resources2003–2011
- Novel Vaginal Microbicides Based On Stable Aav-Neutralizing Antibody Gene TransfeNational Institute Of Allergy And Infectious Diseases2010
- Novel Vaginal Microbicides Based On Stable Aav-Neutralizing Antibody Gene TransfeNational Institute Of Allergy And Infectious Diseases2008–2009
- Generation Of A Therapeutic Antibody Directed Against CCR4 For Patients WithNational Cancer Institute2008
- Studies Of CCR5 Conformational Heterogeneity &Hiv EntryNational Institute Of Allergy And Infectious Diseases2004–2008
- Human Antibodies And Targeted Vaccines Against SARS-COVNational Institute Of Allergy And Infectious Diseases2004–2008
- Role Of SHP-1 Deregulation In HTLV-1 LeukemogenesisNational Cancer Institute2004–2008
- Human Anti-Macaque CCR5 Mabs For Passive ImmunotherapyNational Institute Of Allergy And Infectious Diseases2003–2007
- Genetic Retargeted Human T-Cells For RCC ImmunotherapyNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- Anti-Hiv-1 TAT Human SFV Intrabody Gene TherapyNational Center For Research Resources2004
- Targeting Human Cyclin T1 To Inhibit HIV-1 ReplicationNational Institute Of Allergy And Infectious Diseases2003–2004
- Global Analysis Of Transcriptional Deregulation By HIV-1National Institute Of Allergy And Infectious Diseases2002–2003
- Role Of Grb3-3 In T-Cell Activation &Hiv-1 ReplicationNational Institute Of Allergy And Infectious Diseases2001–2003
- Intraceullular Anti-Tat Antibodies For AIDS Gene TherapyNational Institute Of Allergy And Infectious Diseases2000–2002
- Gene Therapy By Phenotypic Knockout Of HIV CoreceptorsNational Institute Of Allergy And Infectious Diseases1998–2002
- Human Antitat Intrabody Gene Therapy Against SHIVNational Center For Research Resources1999–2001
- Intracellular Antitat Antibodies For AIDS Gene TherapyNational Institute Of Allergy And Infectious Diseases1995–1999
- Gene Therapy Aids--A Recombinant Antibody-Based StrategyNational Institute Of Allergy And Infectious Diseases1994–1997
- Repertoire Cloning Of Anti-Hiv-1 Gp120/Gp41 AntibodiesNational Institute Of Allergy And Infectious Diseases1993–1997
- Mechanism Of Action Of The TAT Product Of HIV-1National Institute Of Allergy And Infectious Diseases1993
- Cd23--Autocrine Growth Factor And ReceptorNational Cancer Institute1989–1991
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: